These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 2408066)

  • 1. Potassium channels in cardiac arrhythmias: focus on antiarrhythmic drug action.
    Rials SJ; Friehling TD; Marinchak RA; Kowey PR
    Prog Clin Biol Res; 1990; 334():111-21. PubMed ID: 2408066
    [No Abstract]   [Full Text] [Related]  

  • 2. [Potassium channels and arrhythmia].
    Funck-Brentano C
    Arch Mal Coeur Vaiss; 1992 Dec; 85 Spec No 4():9-13. PubMed ID: 1307198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electrophysiologic changes in heart failure: focus on pacemaker channels.
    Sartiani L; Stillitano F; Cerbai E; Mugelli A
    Can J Physiol Pharmacol; 2009 Feb; 87(2):84-90. PubMed ID: 19234571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protecting the heart against arrhythmias: potassium current physiology and repolarization reserve.
    Roden DM; Yang T
    Circulation; 2005 Sep; 112(10):1376-8. PubMed ID: 16145010
    [No Abstract]   [Full Text] [Related]  

  • 5. Antiarrhythmic effect of ischemic preconditioning during low-flow ischemia. The role of bradykinin and sarcolemmal versus mitochondrial ATP-sensitive K(+) channels.
    Driamov S; Bellahcene M; Ziegler A; Barbosa V; Traub D; Butz S; Buser PT; Zaugg CE
    Basic Res Cardiol; 2004 Jul; 99(4):299-308. PubMed ID: 15221348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fast and furious: new ways to think about, study and treat cardiac arrhythmias.
    Joyner MJ; Nattel S
    J Physiol; 2009 Apr; 587(Pt 7):1383-4. PubMed ID: 19336610
    [No Abstract]   [Full Text] [Related]  

  • 7. [Pharmacology of antiarrhythmia agents: the new aspects].
    Kaverina NV; Chichkanov GG
    Eksp Klin Farmakol; 2003; 66(2):46-52. PubMed ID: 12962048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphorylation of the IKs channel complex inhibits drug block: novel mechanism underlying variable antiarrhythmic drug actions.
    Yang T; Kanki H; Roden DM
    Circulation; 2003 Jul; 108(2):132-4. PubMed ID: 12835205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Future of antiarrhythmic drugs.
    Darbar D; Roden DM
    Curr Opin Cardiol; 2006 Jul; 21(4):361-7. PubMed ID: 16755206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical significance of the use-dependent sodium channel block and reverse use-dependent potassium channel block of class I and class III antiarrhythmic agents and their values to predict drug efficacy].
    Sadanaga T; Ogawa S; Okada Y; Handa S
    Jpn Circ J; 1992; 56 Suppl 5():1474-6. PubMed ID: 1337923
    [No Abstract]   [Full Text] [Related]  

  • 11. On the mechanism of action of antiarrhythmic agents.
    Grant AO
    Am Heart J; 1992 Apr; 123(4 Pt 2):1130-6. PubMed ID: 1313200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Model systems for the discovery and development of antiarrhythmic drugs.
    Nattel S; Duker G; Carlsson L
    Prog Biophys Mol Biol; 2008; 98(2-3):328-39. PubMed ID: 19038282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ionic mechanisms in heart muscle in relation to the genesis and the pharmacological control of cardiac arrhythmias.
    Hauswirth O; Singh BN
    Pharmacol Rev; 1978 Mar; 30(1):5-63. PubMed ID: 377312
    [No Abstract]   [Full Text] [Related]  

  • 14. Role of K+ channel activators in cardiac electrophysiology and arrhythmias.
    Antzelevitch C; Di Diego JM
    Circulation; 1992 Apr; 85(4):1627-9. PubMed ID: 1555302
    [No Abstract]   [Full Text] [Related]  

  • 15. [Validity of the study of the electrophysiological effects of anti-arrhythmia drugs in man prior to modern antiarrhythmic therapy. Multicenter study].
    Disertori M; Furlanello F; Botti G; Bonatti V; Critelli G; Adinolfi L; Lotto A; Finzi A; Masoni A; Alboni P; Rizzon P; Di Biase M; Salerno JA; Chimienti M; Costantini M; Santini M; Dini P
    Boll Soc Ital Cardiol; 1980; Suppl():101-15. PubMed ID: 6760884
    [No Abstract]   [Full Text] [Related]  

  • 16. [Biochemical basis of the electrophysiological mechanisms in arrhythmias in prior subjection to therapy].
    Ledda F; Mugelli A
    Boll Soc Ital Cardiol; 1980; Suppl():83-90. PubMed ID: 6297526
    [No Abstract]   [Full Text] [Related]  

  • 17. RSD1000: a novel antiarrhythmic agent with increased potency under acidic and high-potassium conditions.
    Yong SL; Xu R; McLarnon JG; Zolotoy AB; Beatch GN; Walker MJ
    J Pharmacol Exp Ther; 1999 Apr; 289(1):236-44. PubMed ID: 10087010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glibenclamide attenuates the antiarrhythmic effect of endotoxin with a mechanism not involving K(ATP) channels.
    Iskit AB; Erkent U; Ertunc M; Guc MO; Ilhan M; Onur R
    Vascul Pharmacol; 2007 Feb; 46(2):129-36. PubMed ID: 17064967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The expression of arrhythmic related genes on Xenopus oocytes for evaluation of class III antiarrhythmic drugs from ocean active material].
    Xu DH; Xu SB
    Yi Chuan Xue Bao; 2000; 27(3):195-201. PubMed ID: 10887690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potassium channel openers and blockers: do they possess proarrhythmic or antiarrhythmic activity in ischemic and reperfused rat hearts?
    Tosaki A; Szerdahelyi P; Engelman RM; Das DK
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1355-62. PubMed ID: 8263798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.